Interestingly, dasatinib exhibited an opposite effect in NCI-N87 gastric cancer cells deficient in E-cadherin (N87-CDH1−/−), with these cells having superior survival after treatment compared to WT cells (N87-WT) (Figure S2). This evidence concerns the gene CDH1 and gastric cancer.